Vanarsa Kamala, Mohan Chandra
Department of Internal Medicine, Rheumatic Divisions Department, UT Southwestern Medical Center 5323 Harry Hines Boulevard, Dallas, TX 75390-8884 USA.
F1000 Med Rep. 2010 Dec 8;2:87. doi: 10.3410/M2-87.
Most rheumatic autoimmune diseases are complex in terms of their genetic origins and underlying pathogenic processes. Non-hypothesis-driven scanning platforms are adding novel insights to our understanding of these multifactorial diseases. This review summarizes the handful of recent proteomic studies that have been executed using samples from patients with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, osteoarthritis, or Sjogren's syndrome. The candidate biomarkers that have been uncovered in the reviewed studies have potential applications in diagnosis, prognosis, and theranostics. Though we are at the infancy of the proteomics era in rheumatology, the limited number of molecules uncovered thus far already hold promise. Ongoing research in proteomics holds tremendous potential for shaping how rheumatic diseases are diagnosed, prognosticated, and managed clinically over the coming years.
大多数风湿性自身免疫性疾病在遗传起源和潜在致病过程方面都很复杂。非假设驱动的扫描平台正在为我们对这些多因素疾病的理解增添新的见解。本综述总结了最近使用类风湿关节炎、系统性红斑狼疮、强直性脊柱炎、骨关节炎或干燥综合征患者样本进行的一些蛋白质组学研究。在这些综述研究中发现的候选生物标志物在诊断、预后和治疗诊断方面具有潜在应用。尽管我们正处于风湿病蛋白质组学时代的初期，但迄今为止发现的有限数量的分子已经展现出前景。蛋白质组学的持续研究在未来几年塑造风湿性疾病的临床诊断、预后评估和管理方式方面具有巨大潜力。
